TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients~* Patients with acute lymphoblastic leukemia (ALL) undergoing first induction chemotherapy within the GMALL-Elderly 1/2003 protocol~* Females of childbearing potential (less than 2 years post-menopausal) must be surgically incapable of pregnancy, or practicing an acceptable method of birth control with a negative pregnancy test (blood or urine) at baseline~* Understanding of the study's rationale and procedures documented in the patient's informed consent~* Ability and agreement to comply with all study requirements~* Patient willing to attend hospital appointments for each visit (infusions will be performed in hospital, under strict medical supervision).~Exclusion Criteria:~* Known hypersensitivity to amphotericin B or LAMB or any of its constituents, in particular known history of anaphylactic reaction to amphotericin B or LAMB or any of its constituents~* Signs or symptoms of IFI or previous proven or probable IFI in the medical history~* Evidence for pulmonary infiltrates in chest CT and/or x-ray of the chest (only when a chest CT/x-ray is done at baseline)~* Estimated creatinine clearance (ECC) ≤ 60 mL/min (Cockcroft-Gault); in such cases the body surface adjusted Modification Diet in Renal Disease (MDRD) glomerular filtration rate (GFRMDRD) should be calculated. If the body surface adjusted GFRMDRD is above 60 mL/min, the patient can be included.~* Patient with moderate or severe liver disease as defined by AST, ALT or alkaline phosphatase (AP) \> 5 times the upper limit of normal (ULN), or bilirubin \> 3 times ULN~* Patients who are unlikely to survive more than 1 month~* Febrile patients (≥ 38.5°C)~* Patients who have received systemic antifungal therapy within 15 days prior to the inclusion~* Any severe co-morbidity other than the underlying hematological disease (ALL), which in the investigator's judgment may interfere with study evaluations or affect the patient's safety~* Patients previously included in this study~* Patients who have taken any investigational drug within the last 30 days prior to inclusion except drugs used according to the GMALL-Elderly/2003 protocol~* Patients who participate in another clinical trial except anti-cancer trials

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women over 18 years~* Free and informed consent signed~* Histologically confirmed adenocarcinoma of the breast, metastatic or non-metastatic~* LVEF\> 50% angioscintigraphy before the start of treatment with Herceptin ®,~* Overexpression of HER2 in the invasive component of the primary tumor (3 + 2 + according to ICH or with confirmation of positivity by FISH or CISH)~* Patient receiving treatment with Herceptin ®,~* Inclusion in the control group: patients treated with Herceptin ® episode without LV dysfunction,~* For the inclusion in the Group LV dysfunction: the appearance of a decrease in LVEF during treatment with Herceptin ®, angioscintigraphy identified.~Exclusion Criteria:~* Heart disease or serious medical conditions do not allow to administer Herceptin ® (documented history of heart failure, angina requiring treatment, severe dyspnoea at rest or oxygen dependency),~* History of ischemic heart disease or myocarditis~* Known allergy to trastuzumab, murine proteins or any of the excipients~* Patients with an indication against the MRI (claustrophobia, ferromagnetic foreign body, pacemaker or implantable defibrillator, known allergy to gadolinium salts)~* Renal impairment (creatinine clearance \<60 ml / min according to the MDRD formula)~* Arrhythmia atrial fibrillation,~* Contraindications to the administration of Dotarem ®,~* Patient unable to give informed consent,~* Adult Trust,~* Pregnant or lactating~* Patient unable to undergo a medical for geographical, social or psychological.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LV dysfunction group (Type: OTHER): Cardiac MRI
- Control group (Type: OTHER): Cardiac MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Psoriatic lean cohort (BMI between 18-24.9 Kg/m2): moderate to severe plaque-type, at least 5% of BSA~* Psoriatic obese cohort (BMI between 30-40 Kg/m2): moderate to severe plaque-type, at least 5% of BSA~* Lean/non-psoriatic cohort: BMI between 18-24.9 Kg/m2~* Overweight/obese non-psoriatic cohort: BMI between 30-40 Kg/m2~* Subjects must be 18-65 years of age~Exclusion Criteria:~* Having received any systemic treatment for psoriasis within the last 30 days~* history of bleeding disorder~* weight loss of 10 pounds in the last four weeks~* current smoker~* Known diagnosis of any unrelated autoimmune disease or inflammatory disease ( i.e. lupus, atopic dermatitis, rheumatoid arthritis).~* Currently taking NSAIDS, aspirin, (if \> once a week, stopped \<30 days ago). Aspirin 81mg may be permitted if the Framingham Risk Score is \< 10~* Having received any anti-inflammatory medication within the last 30 days~* Current use of any anti-coagulants~* LFTs \> 2 x upper normal limits~* HIV infection~* Pregnant~* Less than 6 weeks post partum~* history of cardiovascular disease (MI, CHF, CVA)~* Any cancer diagnosis within the last 5 years~* Symptoms of acute illness such as upper respiratory infection, bronchitis, gastroenteritis, or fever within 3 days of Visit 1~* Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data~* ingestion of DHA or fish oil within last 90 days~* hypertension as defined as \> 140 systolic and \> 90 diastolic after 10 minutes of resting on 2 antihypertensives~* Use of statins within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- lean (BMI≤ 24.9 Kg/m2) (Type: None): Adipose tissue biopsy (fat biopsy) in 9 lean (BMI≤ 24.9 Kg/m2)
- obese (BMI= 30-40 Kg/m2) (Type: None): 9 obese (BMI= 30-40 Kg/m2)
- psoriatic lean (Type: None): 9 psoriatic lean
- psoriatic obese (Type: None): 9 psoriatic obese

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Extension Study of Dexpramipexole in ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has the ability to understand the purpose and risks of the study and provide signed and dated informed consent (or have the consent confirmed by a witness if unable to write) and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.~* Subject was enrolled in either CL211 (NCT00931944) or Study 223AS302 (NCTO1281189).~* Subject has completed their last visit in Study CL211 (NCT00931944) or Study 223AS302 (NCTO1281189).~* Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 1 month (females) or 3 months (males) after their last dose of study treatment.~Exclusion Criteria:~* Subject withdrew prematurely from Study CL211 (NCT00931944) or Study 223AS302 (NCTO1281189).~* Subject permanently discontinued study treatment in Study CL211 (NCT00931944) or Study 223AS302 (NCTO1281189) for any reason other than enrollment into this study.~* Subject from Study CL211 (NCT00931944) or Study 223AS302 (NCTO1281189) has a significant change in medical history (including laboratory tests or a clinically significant condition) that in the opinion of the Investigator would impair the subject's medical fitness for participation and preclude treatment.~* Female subject who is pregnant or breastfeeding.~* Subject is currently enrolled in any investigational drug study other than Study CL211 (NCT00931944) or Study 223AS302 (NCTO1281189).~* Subject is taking pramipexole, other dopamine agonists, any other agent with dopaminergic activity, or any other disallowed concomitant medication.~* Subject is unwilling or unable to comply with the requirements of the protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the protocol. At a minimum, subjects who are not able to travel to the study site must be willing to agree to remote blood draws for clinical laboratory evaluations and telephone visits to report Adverse Events, concomitant medications, and Amyotrophic Lateral Sclerosis Functional Rating Scale (revised) (ALSFRS-R) scores.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dexpramipexole (Type: EXPERIMENTAL): Dexpramipexole open-label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Written Versus Verbal Education for Mild Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmation of a likely concussion without hospital admission~* Participants live locally with a fixed address~* Participants experience at least one new symptom~Exclusion Criteria:~* Participants who cannot understand/read English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Written Education (Type: ACTIVE_COMPARATOR): None
- Verbal Education (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Weight Bearing After Total Hip and Knee Replacement

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* received a THA or TKA in the mentioned period of time~* is able to walk on crutches~* is able to understand our recommendations~* signed informed consent~Exclusion Criteria:~* not able to walk on crutches~* not able to understand our recommendations~* other deformities of lower limbs

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TKA/THA (Type: None): All patients receiving TKA/THA meeting inclusion but not exclusion criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Role of Blood Management in Perioperative Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Anemic patients (defined as Hgb \< 11g/dL within 30 days of initial consult visit)~* Greater than 18-years of age with abnormal uterine bleeding or fibroids~* Scheduled for gynecologic surgery (myomectomy or hysterectomy by laparoscopic, robotic, vaginal or open routes)~Exclusion Criteria:~* Malignancy~* Pregnancy~* Sickle cell anemia or other blood dyscrasias~* Women who received blood transfusions within 30 days prior to surgery~* Women receiving EPO therapy~* Women who have undergone gastric bypass surgery~* Women on therapeutic/full anticoagulation~* Patients undergoing hysteroscopic myomectomy alone without will not be included in the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blood mangement group (Type: EXPERIMENTAL): The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels \<11.0 g/dL. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
- Usual care (Type: ACTIVE_COMPARATOR): Usual care per surgeon preference can include iron by mouth or no iron therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Delayed Cord Clamping in Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* premature infants at 24-28 completed weeks gestation at the time of delivery~* informed consent obtained from parents prior to delivery~Exclusion Criteria:~* multiple gestation (twins, triplets, etc)~* prolonged fetal bradycardia~* placental abruption or previa~* maternal illness~* major congenital anomalies~* maternal fever in labor~* fetal illness (e.g. isoimmune hemolysis)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Minute
- Healthy Volunteers: f

Study Arms:
- Delayed cord clamping (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must understand and voluntarily sign an informed consent form.~* Must be ≥ 18 years of age at the time of signing the informed consent form.~* Must be able to adhere to the study visit schedule and other protocol requirements.~* Biopsy-proven T-cell Non-Hodgkin's Lymphoma, either:~  * Peripheral T-cell Lymphoma (PTCL) whatever the subtype, or~ * Cutaneous T-cell Lymphoma (CTCL), but only the subtype mycosis fungoides.~* Relapsed or refractory to previous therapy for T-cell Non-Hodgkin's Lymphoma.~* Must have received at least one prior combination chemotherapy regimen. There is no limit on the number of prior therapies.~Exclusion Criteria:~* Cutaneous T-cell Lymphoma of subtype Sézary Syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Open-label, oral lenalidomide monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 0 to 18 years~* solid malignancy~* Lansky score \>70%~* more than 17 days since the beginning of the last chemotherapy cycle~* absolute neutrophil count (ANC) greater than 1×109/l~* no administration of any hematopoietic growth factor in the previous 8 days~Exclusion Criteria:~* clinical or biological conditions precluding the mobilization or collection procedure

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Macular Pigment Augmentation on Dark Adaptation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 60 to 80 years old~* \< +- 4.00 diopters spherical equivalent~* normal eye health or early age-related macular degeneration~Exclusion Criteria:~* neurological conditions that can impair vision~* diabetes

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Placebo Comparator (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lower Inspiratory Oxygen Fraction for Preoxygenation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A patient who is scheduled for an elective surgery and required for general anesthesia with endotracheal intubation.~2. Age of the patient is between 20 and 65 years old.~3. Patient's American Society of Anesthesiologists (ASA) Physical Status is I- III.~Exclusion Criteria:~Patients who:~1. Have difficult airway for ventilation or intubation.~2. Have severe lung disease (including any acute respiratory infection).~3. Had past history of coronary artery disease or myocardial infarction.~4. Have severe heart failure (NYHA Fc ≥III).~5. Have liver cirrhosis (Child-Pugh's score ≥B).~6. Have acute or chronic kidney disease (Creatinine ≥2 mg/dl).~7. Have severe anemia (hemoglobin ≤8 mg /dl).~8. Have a body mass index (BMI) ≥35.~9. Are currently pregnant.~10. Have inadequate fasting time, intestinal obstruction or severe gastroesophageal reflux.~11. Scheduled for an emergency surgery, cardiac surgery, craniotomy, or pulmonary surgery.~12. Have mental incapacitant, confusion, dementia, mental retardation, or are unable to complete the consent independently.~13. Refuse to participate in this study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pure oxygen group (Type: ACTIVE_COMPARATOR): The patients receive 100% oxygen therapy during the induction phase of induction
- Lower oxygen group (Type: EXPERIMENTAL): The patients received 60% oxygen therapy during the induction phase of induction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vitamine D Treatment in Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NYHA II-IV~* vitamin D level between 10-30 ng/ml~* ejection fraction by ultrasound \< 40 %~Exclusion Criteria:~* blood calcium \> 2,6 mmol/l~* urinary calcium \> 0,1 mmol/body weight kg/die~* blood phosphorus \> 1,45 mmol/l~* nephrolithiasis in the history~* GFR \< 30 ml/min~* vitamin D injection in the last 6 month~* actual 1,25-OH2-D3 vitamin treatment~* Myocardial infarction or serious coronaria stenosis in the anamnesis uncontrolled atrial fibrillation~* serious valve disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 25-OH-D3 vitamin (Type: EXPERIMENTAL): 180 000 IU 25-OH-D3 vitamin oil per os, per month in the 0, 1, 2, 3, and 6 month at the visit. The patient take the drug under medical control
- MCT oil (Type: PLACEBO_COMPARATOR): 9 ml MCT oil as placebo in the 0,1,2,3,6 month at the visit, under medical contol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues